Shukra Pharmaceuticals Intrinsic Value
Shukra Pharmaceuticals intrinsic value. Shukra Pharmaceuticals (SHUKRAPHAR) median intrinsic value is ₹28.20 from 5 valuation models (range ₹21–₹41), vs current price ₹70.49 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Shukra Pharmaceuticals dividend payments for the complete payout history and dividend yield track record.
SHUKRAPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Shukra Pharmaceuticals intrinsic value across 5 models vs current price ₹70.49 — upside/downside and value range per method. For current market price and key ratios, visit Shukra Pharmaceuticals share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹40.91 | ₹36.82 - ₹45.00 | -42.0% | Book Value/Share: ₹20.45, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹21.15 | ₹19.04 - ₹23.27 | -70.0% | Revenue/Share: ₹6.36, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹28.20 | ₹25.38 - ₹31.02 | -60.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹28.20 | ₹22.56 - ₹33.84 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| Dividend Yield Method | dividend | ₹21.15 | ₹19.04 - ₹23.27 | -70.0% | DPS: ₹0.01, Target Yield: 2.5% |
SHUKRAPHAR Intrinsic Value vs Market Price — All Valuation Models
Shukra Pharmaceuticals fair value range ₹21–₹41 vs current market price ₹70.49 across 5 valuation models. Compare with SHUKRAPHAR fair value to assess whether the stock is under or overvalued.
SHUKRAPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Shukra Pharmaceuticals median intrinsic value ₹28.20, current price ₹70.49 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of SHUKRAPHAR?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Shukra Pharmaceuticals (SHUKRAPHAR) is ₹28.20 (median value). With the current market price of ₹70.49, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹21.15 to ₹40.91, indicating ₹21.15 - ₹40.91.
Is SHUKRAPHAR undervalued or overvalued?
Based on our multi-method analysis, Shukra Pharmaceuticals (SHUKRAPHAR) appears to be trading above calculated value by approximately 60.0%.
SHUKRAPHAR Financial Health — Key Ratios vs Industry Benchmarks
Shukra Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 16.80 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -8.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.24x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SHUKRAPHAR Cash Flow Quality — Operating & Free Cash Flow
Shukra Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹3 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |